Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Arthur He CFA from H.C. Wainwright maintained a Buy rating on the stock and has a $10.00 price target.

Arthur He CFA has given his Buy rating due to a combination of factors related to Prime Medicine, Inc.’s promising developments in their gene editing programs. The company is on track to deliver initial clinical data for its lead product candidate, PM359, by 2025. This candidate targets chronic granulomatous disease and could potentially showcase the advantages of prime editing over other gene editing techniques. A positive outcome from these studies could act as a significant catalyst for the stock, with plans to initiate a pivotal study in 2026.
Additionally, Prime Medicine is making steady progress with PM577, aimed at treating Wilson’s Disease. The company plans to file an IND for PM577 by the first half of 2026, with clinical data expected in 2027. Financially, despite reporting a net loss for 2024, Prime Medicine has a strong cash position of approximately $205 million, which is expected to support ongoing operations. The Buy rating is supported by a risk-adjusted net present value analysis, leading to a 12-month price target of $10 per share, factoring in future revenue projections and current financial standing.